Lynx Dx INC

Claim this page

Their homepage, crawled JUL 31, 2026

At a glance

EmployeesNot reported

In business sinceNot reported

Industry

In-Vitro Diagnostic Substance Manufacturing

HeadquartersAnn Arbor, MI

SAM.gov UEICVMDCVXNU3K1

Lynx Dx develops MyProstateScore 2.0 (MPS2), a urine test that analyzes 18 gene transcripts to assess prostate cancer risk for physicians and patients. The test can be run using biomarkers alone or combined with clinical risk factors, and includes at-home sample collection options. The company serves the healthcare provider and patient markets for prostate cancer risk assessment.

Facility	City	State	Employees	Status
Lynx Dx INC	Ann Arbor	MI	—	● ACTIVE

Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.